Should polymyxin be used empirically to treat infections in patients under high risk for carbapenem-resistant Acinetobacter?
Felipe F
FF
Tuon
Andrea M
AM
Rymsza
Sergio R
SR
Penteado-Filho
Marcelo
M
Pilonetto
Lavinia N
LN
Arend
Anna S
AS
Levin
D000150:Acinetobacter / Q000187:drug effects / Q000302:isolation & purification; D000151:Acinetobacter Infections / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D016470:Bacteremia / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality; D001938:Brazil; D015780:Carbapenems / Q000627:therapeutic use*; D002648:Child; D003428:Cross Infection / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011113:Polymyxins / Q000627:therapeutic use*; D016019:Survival Analysis; D055815:Young Adult; D018440:beta-Lactam Resistance
D000900:Anti-Bacterial Agents; D015780:Carbapenems; D011113:Polymyxins